Molecular biology of squamous cell carcinoma of the head and neck: relevance and therapeutic implications (Q37788246)

23 August 2017

title

Molecular biology of squamous cell carcinoma of the head and neck: relevance and therapeutic implications (English)

1 reference

head and neck squamous cell carcinoma

23 August 2017

0 references

1 reference

Sandra Schmitz

1

1 reference

23 August 2017

Jean-Pascal Machiels

series ordinal

2

1 reference

23 August 2017

publication date

1 September 2010

1 reference

Expert Review of Anticancer Therapy

23 August 2017

published in

1 reference

23 August 2017

volume

10

1 reference

23 August 2017

issue

9

1 reference

23 August 2017

page(s)

1471-1484

1 reference

The mechanics of base excision repair, and its relationship to aging and disease

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Epidemiology of carcinogen metabolism genes and risk of squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Nucleotide excision repair core gene polymorphisms and risk of second primary malignancy in patients with index squamous cell carcinoma of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Oral status, oral infections and some lifestyle factors as risk factors for oral and oropharyngeal squamous cell carcinoma. A population-based case-control study in southern Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Clinical implications of human papillomavirus in head and neck cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Defining molecular phenotypes of human papillomavirus-associated oropharyngeal squamous cell carcinoma: validation of three-class hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Human papillomavirus, p16 and p53 expression associated with survival of head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

A review of inherited cancer syndromes and their relevance to oral squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Focus on head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Genetic signatures of HPV-related and unrelated oropharyngeal carcinoma and their prognostic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Epidermal growth factor receptor (EGFR) signaling in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Epidermal growth factor receptor biology in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Co-regulation of B-Myb expression by E2F1 and EGF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Identification of a novel EGF-sensitive cell cycle checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Platinum-based chemotherapy plus cetuximab in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Mechanisms for oncogenic activation of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Met, metastasis, motility and more

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

21 January 2018

The Ras/Raf/MAPK pathway

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

A novel activating role of SRC and STAT3 on HGF transcription in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Association of extracellular cleavage of E-cadherin mediated by MMP-7 with HGF-induced in vitro invasion in human stomach cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Angiogenic heterogeneity in head and neck squamous cell carcinoma: biological and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Insulin-like growth factors and neoplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Insulin-like growth factor receptor as a therapeutic target in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Inflammation and breast cancer. Microenvironmental factors regulating macrophage function in breast tumours: hypoxia and angiopoietin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Mechanism of biological synergy between cellular Src and epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

The development of proteasome inhibitors as anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Role of activated nuclear factor-kappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.115

21 January 2018

Identifiers

DOI

10.1586/ERA.10.115

1 reference

23 August 2017

1 reference